The inconsistent data regarding the impact of exogenous insulin treatment on breast cancer risk may be attributable to the fact that exogenous insulin treatment is designed to restore normal circulating insulin concentrations in those with insufficient β-cell function; thus, it likely does not create hyperinsulinemia in most cases. Here, INS is linked to Hyperinsulinemia.